Dementia Prevention
Nearly half of dementia cases worldwide are tied to 14 risk factors that can be changed, and most of them are the same things that protect the heart. Hearing loss is the biggest single one — mainly because it is so common, not because it is so dangerous.
The 2024 Lancet Commission on dementia prevention estimates that eliminating 14 modifiable risk factors would prevent or delay about 45% of dementia cases globally. Acting on them is the most impactful thing most adults can do for long-term cognitive health — with one honest caveat that runs through this whole page: so far only one large randomised trial built around dementia as its main outcome has shown fewer diagnoses — blood-pressure lowering, in a village-level trial in rural China. Beyond that, what exists is a strong risk-factor map, several trials that move cognition, and natural experiments with the shingles vaccine that suggest fewer dementia diagnoses, though how large that effect is remains disputed.
The Lancet Commission framework
Moderate — a careful synthesis of observational evidence, but the estimates assume causality and are not trial-derived.
The 2024 Lancet Commission update ranks modifiable risk factors by population attributable fraction — the share of dementia cases that would not occur if the risk factor were eliminated from the population.[1] Two factors were new in 2024: high LDL ("bad") cholesterol in midlife, and untreated vision loss in late life.
| Life stage | Risk factor | Risk multiplier | How common | Share of cases |
|---|---|---|---|---|
| Early life (<45) | Less education | 1.6× | 23% | 5% |
| Midlife (45–65) | Hearing loss | 1.4× | 59% | 7% |
| Midlife | High LDL cholesterol (new 2024) | 1.3× | 77% | 7% |
| Midlife | Depression | 2.2× | 7% | 3% |
| Midlife | Traumatic brain injury | 1.7× | 12% | 3% |
| Midlife | Physical inactivity | 1.2× | 28% | 2% |
| Midlife | Smoking | 1.3× | 22% | 2% |
| Midlife | Diabetes | 1.7× | 9% | 2% |
| Midlife | Hypertension | 1.2× | 31% | 2% |
| Midlife | Obesity | 1.3× | 13% | 1% |
| Midlife | Excessive alcohol | 1.2× | 13% | 1% |
| Late life (65+) | Social isolation | 1.6× | 24% | 5% |
| Late life | Air pollution (fine particulates) | 1.1× | 75% | 3% |
| Late life | Untreated vision loss (new 2024) | 1.5× | 13% | 2% |
| All 14 combined | 45% |
Two things in that table are worth more attention than the headline number.
The ranking is driven by how common a factor is, not how dangerous it is. Hearing loss tops the list with a fairly ordinary risk multiplier of 1.4 — it wins because 59% of the relevant population has it. Depression carries by far the largest individual risk of the 14 (2.2×) but affects 7% of people, so it contributes a modest 3%. Hypertension's small share is often misread as "blood pressure doesn't matter much for the brain". Its individual effect on dementia risk is genuinely modest (1.2×), despite being present in 31% of adults, but a small population share does not mean a small payoff from treatment: in a large randomised trial with dementia as its primary outcome, lowering blood pressure reduced dementia diagnoses by about 15% (see below).
Ten of the 14 are midlife factors. Late life contributes only three — social isolation, air pollution and uncorrected vision loss. The window that matters most is roughly ages 45 to 65.
These fractions assume the associations are causal, which for some factors is uncertain. The Commission itself flags that late-life depression may be an early symptom of brewing dementia rather than a cause, and that removing a risk factor across a population does not guarantee any individual avoids dementia (Caution — these are population averages, not personal predictions). When the full 14-factor model was re-tested inside a single long-running cohort of 5,526 Americans, only three factors survived — hearing loss and diabetes as risks, and midlife hypertension in the protective direction — leading those authors to warn that meta-analytic estimates may be inflated by publication bias. That analysis is a conference abstract rather than a peer-reviewed paper, so treat it as a caution flag rather than a refutation.[2]
The biggest individual levers
1. Treat hearing loss
Moderate for the observational signal; the one randomised trial was null on its primary outcome.
- The largest single factor in the Commission's model — tied with high LDL cholesterol at a rounded 7% share — and the one most people leave untreated for years.
- The ACHIEVE trial — 977 US adults aged 70–84 with untreated hearing loss, randomised to hearing aids and audiological counselling or to health education — was null on its primary outcome: three-year cognitive decline was essentially identical in the two groups.[3] The much-quoted 48% slowing came only from a pre-specified higher-risk subgroup (participants drawn from a long-running cardiovascular cohort, who were older and declining faster) — encouraging but hypothesis-generating (Weak/preliminary for the subgroup benefit). The underlying case for treating hearing loss still rests on its large population share and the low harm of the intervention.
- A 2026 target trial emulation — an observational analysis designed to mimic a randomised trial, not an actual trial — followed 2,777 Australians aged around 75 with self-reported hearing problems (not measured by audiometry) for seven years. Dementia occurred in 5.0% of those prescribed hearing aids versus 7.5% of those not (a relative risk of 0.67, i.e. about a third lower; in absolute terms roughly 25 fewer cases per 1,000 people over seven years), with risk falling stepwise by how often the aids were actually worn — an imprecise contrast on its own, and the authors cannot rule out residual confounding. Cognitive test scores among survivors barely moved, so the benefit shows up as crossing the diagnostic threshold rather than as sharper thinking day to day.[4]
- Mechanisms: reduced cognitive load from straining to hear; preserved social engagement; reduced isolation. The isolation pathway has some randomised support: in a secondary analysis of ACHIEVE, people given hearing aids and counselling kept about one more person in their social network over three years than the health-education group and reported slightly less loneliness — detectable, but the authors judge the loneliness change too small to matter clinically and are unsure whether the network change does.[5]
- Action: get audiometry if any decline is suspected. If you pass a standard audiogram but struggle in noise, ask for extended high-frequency audiometry, which tests the range above the standard 8 kHz ceiling; one analysis suggests it explains more of the difficulty understanding speech in noise than the standard test does — about a third of the variance against roughly a fifth (unadjusted), though that comparison comes from a single small, not-yet-peer-reviewed preprint of 263 mostly normal-hearing adults and should be treated as provisional.[6] Hearing aids are not vanity, modern devices are small and effective, and the device that lives in a drawer doesn't count. See Hearing for the full picture.
2. Treat hypertension in midlife
Moderate — one large randomised trial now shows fewer dementia diagnoses; the earlier SPRINT-MIND trial was positive only for milder cognitive impairment.
- SPRINT-MIND tested an intensive systolic blood-pressure target (below 120 mmHg) against the standard (below 140) in 9,361 adults. It cut mild cognitive impairment by about a fifth and the combined mild-impairment-or-dementia endpoint by about 15%, but the pre-specified primary endpoint of dementia alone missed significance — a 17% reduction whose confidence interval still included no effect at all (hazard ratio 0.83, 95% confidence interval 0.67–1.04). That bracketed range is where the true effect most plausibly lies; because it crosses 1.0, the result is compatible with no benefit. The trial was stopped early for cardiovascular benefit and was probably underpowered for dementia.[7] Extended follow-up to a median of about seven years kept the composite endpoint significant while dementia alone remained non-significant.[8]
- The first large trial with dementia as its main outcome to show a reduction came from rural China. In 326 villages, 33,995 adults aged 40 and over with uncontrolled high blood pressure were randomised by village either to a programme in which trained community health workers started and adjusted blood-pressure drugs towards a goal below 130/80 mmHg, or to usual care. Over four years, systolic pressure ended 22 mmHg lower and all-cause dementia, the trial's primary outcome, was about 15% lower (risk ratio 0.85), with fewer serious adverse events, not more.[9] It was open-label, in a single population, and achieved a bigger blood-pressure gap than most real-world care does.
- The 2024 Commission calls for systolic pressure below 130 mmHg from age 40 — a target now supported by one positive dementia trial (the rural-China trial above aimed for below 130/80) as well as by the cognitive-impairment and cardiovascular gains.
- Most effective: lifestyle (the blood-pressure-lowering DASH eating pattern, exercise, weight loss) plus medication if needed. See Blood pressure.
3. Manage cardiometabolic health
Moderate — consistent observational signal; no trial has yet shown that treating diabetes, weight or cholesterol prevents dementia (see Statins below; blood pressure is the exception, section 2).
- Type 2 diabetes raises dementia risk by roughly 70% in the Commission's pooled estimate — substantial, though short of the "doubles your risk" often quoted. Well-controlled diabetes is much less damaging than uncontrolled, though the Commission notes that intensive control is no better for dementia than standard control.[10]
- Midlife obesity is linked to about 30% higher dementia risk (relative risk 1.31), and a larger waist to about 10% higher risk of cognitive impairment or dementia (hazard ratio 1.10); the evidence reviewed here does not show that belly fat matters more than overall weight.[11] In adults over about 60, higher body weight is linked to slightly lower risk, probably because weight often falls in the years before diagnosis, and waist size shows no clear link.[12] The evidence therefore favours keeping weight and waist in check from midlife.
- High LDL cholesterol — the 2024 addition reflects accumulating evidence that the vascular contribution to dementia is larger than previously recognised. It is now tied with hearing loss for the largest share of cases, mostly because three-quarters of middle-aged adults have elevated levels.
- Action: track HbA1c (the three-month blood-sugar average), a lipid panel, blood pressure, and waist circumference. Treat in midlife rather than waiting. See Lipid management.
4. Exercise — both modalities
Moderate for cognition; no trial has shown a dementia-incidence reduction.
- A single trial in 120 older adults found aerobic exercise increased anterior hippocampal volume by about 2%.[13] Pooled trials have not confirmed it. A meta-analysis of eight randomised trials in 554 healthy older adults found no significant effect of aerobic training on hippocampal volume, even though fitness improved, and fitness gains did not track volume change.[14] A 2025 meta-analysis of 12 trials in older adults with hippocampal shrinkage or neurodegenerative disease was also null.[15] Treat "exercise grows the hippocampus" as unproven (Weak).
- Resistance training has an independent signal: a 12-month randomised trial in senior women improved one executive-function measure (selective attention and conflict resolution) by 11–13% while a balance-and-tone control group slightly worsened. One trial, one cognitive domain, one population.[16]
- The best overall evidence comes from a 2026 meta-analysis of 227 randomised trials in adults over 60 without dementia. Exercise alone improved executive function, memory and processing speed compared with control. Combined programmes (exercise plus another lifestyle component, most often cognitive training) beat control only for memory. In a network analysis they edged out exercise alone for executive function and processing speed, and the authors say their added benefit is still unsettled.[17] For resistance training specifically, a 2026 meta-analysis of 17 trials found modest gains in working memory and mental flexibility but no advantage over other exercise, and the evidence was low-certainty.[18]
- The Finnish FINGER trial — a two-year multi-domain programme of diet, exercise, cognitive training and vascular-risk monitoring in 1,260 at-risk older adults — improved cognition, though the absolute between-group difference on the cognitive composite was small (about 0.022 units per year); the eye-catching "25%/83%/150%" figures circulating online are relative differences on composite and sub-scores.[19]
- US POINTER (2025), the large American successor to FINGER, randomised 2,111 at-risk adults aged 60–79 to a structured or a self-guided version of the same multidomain programme (exercise, the MIND diet, cognitive and social engagement, cardiometabolic monitoring). Both arms improved. The structured arm improved more on global cognition, but only by about 0.03 standard deviations per year, and the authors say the clinical meaning of that gap is not yet established. The added benefit was the same in carriers and non-carriers of APOE ε4, the main genetic risk variant for Alzheimer's, but was larger in participants who started with weaker cognition.[20] Two caveats matter. First, the trial had no do-nothing control arm, so it shows that added structure helps rather than that multidomain living prevents decline. Second, it was funded by the Alzheimer's Association, whose staff helped design, run and analyse it; the structured arm also received blueberry rebates from an industry council and used a commercial brain-training product.
- Dose: 150+ minutes of aerobic exercise plus two resistance sessions per week (general exercise guidelines).
- The other side of the coin: prolonged sitting is associated with hippocampal atrophy and white-matter damage. In an older-adult cohort followed for seven years, greater sedentary time tracked with faster hippocampal shrinkage and with declines in naming and processing speed, and the models held after adjusting for moderate-to-vigorous activity; poorer episodic memory and a smaller Alzheimer's-type brain-imaging signature showed up only as snapshot associations.[21] A systematic review of 33 studies points the same way while describing the evidence as limited and mixed.[22] In 14,415 UK Biobank adults aged 45–81, more sedentary time went with more white-matter hyperintensities, a marker of small-vessel disease, with the link strongest at low levels of moderate-to-vigorous activity — so for this outcome, being active does blunt the signal.[23] No trial has shown that cutting sitting preserves brain volume. The often-repeated idea that contracting muscle sends brain-derived neurotrophic factor (BDNF) to the brain does not hold up in humans: exercise raises BDNF production inside muscle, but the muscle-made protein does not appear to enter the bloodstream,[24] and around 70–80% of the BDNF circulating at rest and during exercise comes from the brain itself.[25] Walking about 7,000 steps a day is associated with 38% lower dementia incidence than 2,000 steps, in a dose-response meta-analysis that graded its own dementia evidence as moderate certainty.[26] See Sitting.
5. Sleep — quality, regularity, and screening for apnea
Weak/preliminary for the mechanism; Moderate for the sleep-apnea association; Weak for short and irregular sleep, where reverse causation is likely.
- Deep (slow-wave) sleep is when the brain's waste-clearance system appears most active at removing beta-amyloid — but the direct human evidence is one 17-person crossover study that moved amyloid and not tau, the other core Alzheimer's protein, so this is a plausible mechanism rather than an established one, and total sleep duration is the better-supported target than deep sleep specifically. See Sleep architecture.
- Short sleep is linked to dementia, but the link may run backwards. Pooled cohort studies find people sleeping six hours or less are more likely to be diagnosed within the next decade, yet the excess risk largely disappears in studies following people for more than ten years, so short sleep may be an early symptom rather than a cause.[27]
- Sleep regularity is a newer signal: in UK Biobank adults whose sleep was tracked by wrist sensors for a week, the most irregular sleepers had about 50% higher dementia risk over seven years than typical sleepers (hazard ratio 1.53).[28] That is one cohort with short follow-up, so treat it as preliminary.
- Untreated obstructive sleep apnea (OSA) — repeated breathing interruptions during sleep — is linked to about 40% higher dementia risk, though few studies adjusted for obesity.[29] Continuous positive airway pressure (CPAP) is worth using for its established benefit on daytime sleepiness, but randomised trials so far show only a short-term gain on one test of mental flexibility, and a 2025 trial in 148 cognitively normal middle-aged adults with sleep apnea found no cognitive benefit at six months, so there is no evidence yet that it slows decline.[30][31] See Sleep-disordered breathing.
- Excessive habitual daytime napping (over 60–90 minutes, especially in the morning or with high day-to-day variability) is now read as a behavioural marker of underlying neurodegeneration — see Daytime naps. Long naps are more likely an early sign of dementia than a cause, often reflecting fragmented night-time sleep and amyloid accumulation.
- Action: 7–8 hours, regular schedule, screen for sleep apnea if any indicator. If you've started napping noticeably more than you used to, treat it as a signal worth investigating.
6. MIND-pattern eating, and minimise ultra-processed food
Weak for the dementia-specific claim. Large cohorts show a modest association, and the one randomised trial was null.
- The widely cited "~53% lower Alzheimer's risk" comes from an observational cohort of 923 older adults followed 4.5 years: those in the top third for adherence to the MIND dietary pattern had roughly half the Alzheimer's incidence rate (hazard ratio 0.47, i.e. about 53% lower), a design prone to reverse causation.[32]
- Much larger and longer cohorts find a far smaller association. Among about 130,000 US nurses and health professionals followed for up to four decades, the highest versus lowest MIND adherence was linked to about 14% lower risk of dementia from any cause (hazard ratio 0.86), and Mediterranean-diet adherence to about 21% lower risk (hazard ratio 0.79). Dementia was identified from self-reported diagnoses and death records, and the results are observational.[33]
- The only randomised trial of the MIND diet — 604 older adults at risk, three years — was a clean null: global cognition and brain-imaging outcomes did not differ from the control diet, and both arms improved similarly under mild calorie restriction.[34] The broader Mediterranean/MIND pattern is still worth following on cardiovascular grounds, but the trial does not support a dementia-specific claim.
- A 2026 meta-analysis of eight prospective cohorts (more than 250,000 people) found that the highest ultra-processed food (UPF) intake was linked to about 14% higher risk of cognitive impairment or dementia (hazard ratio 1.14), with large differences between studies. The link was clear in people under 60 but not statistically significant in those over 60. These are observational associations.[35] Whether that reflects processing itself or the poor overall diets these foods travel with is still open, and reviewers call for future studies to measure overall diet quality alongside UPF.[36]
- See Dietary patterns and Ultra-processed food.
7. Social engagement
Moderate — one of the three late-life factors, with a consistent cohort signal.
- Frequent social contact, being married or partnered, and larger social networks all associate with reduced dementia. In the Commission's model social isolation carries about 60% higher risk (relative risk 1.6) and accounts for about 5% of cases — the largest of the three late-life factors, level with less education, and behind only hearing loss and high LDL cholesterol at 7% each.[37]
- Feeling lonely carries risk of its own, separate from how many people you see: a 2024 meta-analysis of 21 cohort samples and more than 600,000 people found about 31% higher risk of dementia in lonely adults (hazard ratio 1.31), and the association held in analyses that adjusted for objective social isolation and/or depression — though the studies measured loneliness in different ways and all of the data are observational.[38]
- Depth of network matters more than the binary "lives alone" — composite measures of social integration (how many kinds of tie a person has, and how often they use them) track health outcomes far more strongly than living arrangements alone. See Purpose.
- Action: maintain regular real-world relationships; volunteer; participate in groups; for older adults, structured social programmes.
8. Stay cognitively engaged
Weak for far transfer — training reliably improves the trained skill; generalisation is limited.
- Educational attainment in early life builds cognitive reserve, and it is the single early-life factor in the Commission's model.
- Continued learning in adulthood — language acquisition, music, complex hobbies — has a cohort signal.
- The ACTIVE trial randomised 2,832 older adults to memory, reasoning or speed-of-processing training. Ten years later the reasoning and speed groups still outperformed controls on the ability they had trained (memory training did not last), and all three trained groups reported less difficulty with everyday activities — but that everyday-function benefit was self-reported rather than performance-measured.[39] After 20 years of insurance-claims follow-up, none of the three training groups as a whole had significantly fewer dementia diagnoses than controls (speed training about 13% lower risk, hazard ratio 0.87, not significant). Speed-trained participants who completed at least one booster session (boosters at 11 and 35 months were offered at random, and only to people who had completed most of the initial training) were about 25% less likely to be diagnosed than the whole control group (hazard ratio 0.75). That comparison is selected by adherence rather than randomised, diagnoses came from billing codes, and one author is a consultant to and stockholder in the company that sells the speed-training software.[40] An independent reanalysis, published as a letter, found that no comparison stays statistically significant once corrected for the number of comparisons, although nearly all the estimates lean toward a small benefit (Weak/preliminary for dementia prevention).[41]
- "Brain training" apps have small, narrow effects with limited transfer to general cognition.
- Action: real-world complex learning (language, music, dancing, demanding skills) beats digital "brain training". See Cognitive engagement.
9. Defend purpose through the retirement years
Moderate for the association; observational and open to reverse causation.
- A 28-year prospective analysis of 4,632 adults in the Wisconsin Longitudinal Study measured sense of purpose at ages 52, 63 and 70 and cognition at 80. Purpose at 52 predicted better cognition but not a clearly lower chance of a dementia-range score (OR 0.93, not significant); purpose measured at 63 and at 70 predicted lower odds of a dementia-range score at about 80 (OR 0.85 per standard deviation at each age, roughly 15% lower odds). "Dementia" was a single telephone-screen cutoff, not a clinical diagnosis, and each age was modelled separately. A slightly steeper decline in purpose between 52 and 70 was found in those who screened in the dementia range at 80, which the authors note could reflect early decline lowering purpose.[42]
- Earlier work in the Rush Memory and Aging Project found that a person scoring high on purpose was about 2.4 times more likely to remain free of Alzheimer's over up to seven years than someone scoring low.[43]
- The retirement years are a sensible time to pay attention to purpose, but the study does not prove a critical window: the age-52 and age-63/70 estimates overlap, and the authors call for more frequent measurements to pin down when purpose matters most.
- Action: plan the next role before the current one ends; build at least one purpose source independent of paid work; maintain weekly contact with a small set of relationships of substance. See Purpose.
What about specific supplements and drugs?
Modest evidence
- Omega-3 (the long-chain fat DHA) — an observational signal, but pooled randomised trials in cognitively healthy older adults show essentially no benefit for global cognition. A small two-year trial in the group often thought most likely to benefit — 365 dementia-free adults aged 55–80 with low dietary DHA intake, nearly half carrying the APOE ε4 risk gene — found that 2 g a day of DHA raised DHA levels in spinal fluid (in carriers and non-carriers alike) but did not change brain volume or cognition; the trial was not powered for those outcomes and dropout was high (38%).[44] Reasonable as part of an overall dietary pattern, not as a stand-alone cognitive supplement (Weak). See Omega-3.
- Vitamin D — correct a deficiency for bone and general health, but don't expect a brain benefit. In 620 adults aged 50 or older with mild-to-moderate deficiency and early cognitive impairment, two years of supplementation did not improve any cognitive measure.[45] A trial of higher doses lasting up to five years, in 2,492 mostly vitamin-D-sufficient older adults, found no clear reduction in dementia diagnoses, though it recorded too few cases (45) to be conclusive (Weak).[46]
- B vitamins (B6, B12, folate) — the VITACOG trial showed slower brain shrinkage specifically in people with mild cognitive impairment and elevated homocysteine — an amino acid that builds up when B-vitamin status is poor — and a re-analysis found even that held only in participants with adequate omega-3 status, a subgroup finding later trials did not cleanly confirm. Routine use in people with normal homocysteine is not supported (Weak). See B vitamins.
- Daily multivitamin — the COSMOS-Mind trial in 2,262 older adults found a daily multivitamin produced a small improvement on a telephone-administered cognitive composite over three years, while cocoa extract did nothing.[47] In a smaller sub-study of the same trial using in-person testing, the multivitamin improved memory but not overall cognition significantly,[48] and cocoa extract again did nothing.[49] Pooling that sub-study with COSMOS-Mind and a third, web-based one gave a small benefit for overall cognition and memory, which the authors equate to about two years less cognitive ageing.[50] All three come from one parent trial testing one commercial product, the endpoints are test scores rather than dementia diagnoses, and the supplements were industry-donated (Weak/preliminary). Worth a neutral mention, not a recommendation.
- Creatine — no cognitive benefit in well-rested adults; the older-adult memory finding vanished when its meta-analysis was redone correctly, and vegetarians gain no more than meat-eaters. The one genuine lead is a single large dose during acute sleep deprivation, which is not a dementia-prevention strategy (Weak). See Creatine.
Weak or negative evidence
- Ginkgo biloba — negative in both large prevention trials: 3,069 older Americans over roughly six years showed no reduction in dementia (if anything a non-significant increase),[51] and 2,854 French adults over five years showed no reduction in Alzheimer's diagnoses.[52]
- Resveratrol — no convincing cognitive trials.
- Curcumin — small studies suggestive; not robust. See Curcumin.
- Most "memory" formulas — unproven mixtures.
Pharmacological
- Anti-amyloid antibodies (lecanemab, donanemab) — modest disease-slowing in early symptomatic Alzheimer's, not prevention in healthy adults. The slowing is real but small in absolute terms: over 18 months lecanemab reduced decline on an 18-point clinical dementia rating scale by 0.45 points — about 27% relative slowing on a score that worsened by 1.66 points in the placebo group.[53] Donanemab produced a similar 0.7-point difference over 76 weeks.[54] Both cause amyloid-related brain swelling (ARIA-E) on MRI in about 13% (lecanemab) and 24% (donanemab, original dosing) of treated patients, mostly without symptoms, with small brain bleeds counted separately on top of that; a slower donanemab dose build-up, adopted in the US label in 2025, lowered swelling to about 16%.[55] People with two copies of the APOE ε4 gene are at highest risk; the European licences for both drugs and the UK licence for lecanemab exclude them, so a gene test is part of eligibility there, while US labels advise testing but do not require it. Treatment also means regular infusions and repeated MRI scans (Moderate for the effect; Caution for the harm profile).
- Shingles (herpes-zoster) vaccine — a striking non-drug signal. A natural experiment in Wales, where a birthdate cut-off made the vaccine abruptly available to people born on or after 2 September 1933 but not to those born a week earlier, found new dementia diagnoses over seven years fell by 3.5 percentage points in absolute terms — a one-fifth relative reduction. The birthdate design mimics randomisation and sidesteps the "healthy-vaccinee" bias of ordinary observational studies.[56] Similar birthdate natural experiments in Australia and Canada found that eligibility for the vaccine lowered new dementia diagnoses by about 2 percentage points over five and a half to seven and a half years,[57][58] and a follow-up in Wales found fewer diagnoses of mild cognitive impairment and fewer deaths from dementia among people already diagnosed.[59] There is a serious objection: once you account for how few eligible people actually got vaccinated, the Australian and Canadian results imply implausibly large effects in those vaccinated — in two of the three analyses (one Australian, two Canadian) more than 100% of their dementia prevented, which is impossible — and national dementia rates did not visibly fall after the programmes started.[60] All of this concerns the older live vaccine. For the now-standard recombinant vaccine (Shingrix) the evidence is observational: recipients had about 17% more dementia-free time than live-vaccine recipients,[61] and among about 510,000 US Medicare beneficiaries aged 66 or older admitted to a skilled-nursing facility, four-year dementia risk was 18.8% with the vaccine against 24.6% without (about a quarter lower; risk ratio 0.76), though the manufacturer funded that study and its own checks suggest some residual confounding.[62] (Moderate that vaccination lowers dementia diagnoses; Weak on how large the effect is; no randomised trial yet.) The vaccine is recommended anyway to prevent shingles, so the dementia question does not change the decision for people already eligible.
- GLP-1 receptor agonists (semaglutide, tirzepatide) — an observational signal for reduced dementia incidence in type 2 diabetes[63], plus a large Swedish register study in which people already diagnosed with depression or anxiety had substantially fewer episodes of psychiatric deterioration while on semaglutide than during their own periods off it. The dedicated phase 3 EVOKE and EVOKE+ trials — 3,808 adults aged 55–85 with early Alzheimer's disease taking oral semaglutide or placebo — showed no slowing of global clinical and functional decline at two years: the differences between groups were about a tenth of a point on an 18-point scale, in opposite directions in the two trials.[64] A spinal-fluid substudy in which markers of Alzheimer's pathology moved in the right direction comes from a manufacturer's conference presentation rather than this peer-reviewed report. The honest read: the strongest dementia-reduction numbers come from observational cohorts (susceptible to confounding), while the head-on trials in established disease were null; the underlying biology can be modulated, but clinical disease isn't being rescued at two years, and the prophylactic-decades-earlier hypothesis is still open (Weak/preliminary; all major trials manufacturer-funded). See GLP-1 receptor agonists.
- Statins — genetic studies suggest that lifelong lower cholesterol through the statin target is linked to less dementia,[65] but the first large randomised trial with dementia in a primary outcome was neutral. In 9,971 adults aged 70 or older without cardiovascular disease, diabetes or dementia, atorvastatin cut major cardiovascular events by about 30% (hazard ratio 0.70) over a median 5.9 years. It did not lengthen survival free of death, dementia or persistent disability, and the published summary reports dementia only as part of that combined outcome.[66] Take a statin for your heart and arteries when indicated, but don't start one late in life to prevent dementia (Weak).
What's overrated
- "Brain training" apps for transferable cognition. The one long-term dementia signal — ACTIVE's speed training with boosters, above — is conditional and fragile, and does not extend to commercial apps in general.
- Mega-doses of B vitamins in people who aren't deficient.
- "Anti-inflammatory" supplement protocols without dietary pattern change.
- Coconut oil for Alzheimer's — anecdotal claims, no robust trial support.
- Benzodiazepine "dementia risk" — the alarming headlines overstate it. In a Dutch cohort of 3,526 older adults followed nearly seven years, benzodiazepine users were no more likely to develop dementia than non-users.[67] A larger cohort of 5,443 cognitively healthy older adults followed for about 11 years found the same overall, with one caveat. People with the highest cumulative use of anti-anxiety benzodiazepines had about 33% higher risk (hazard ratio 1.33), and current users showed faster shrinkage of the hippocampus, the brain's memory hub.[68] The dementia fear is overrated, but there are other reasons to avoid long-term, high-dose use in older adults, such as falls and dependence. (Moderate that the dementia risk is overrated.)
- Anticholinergic drugs — a consistent but partly confounded signal. In the same Dutch cohort, persistent use of strongly anticholinergic drugs roughly doubled dementia risk. The excess largely disappeared when people taking antidepressants and antipsychotics were excluded, but that subgroup was far too small to rule out a real effect.[69] A much larger Swedish study of nearly 200,000 people with dementia found the odds rising with cumulative dose of strong anticholinergics, up to about 66% higher odds (odds ratio 1.66) after three or more years' worth of standard daily doses. The association showed up notably for bladder antispasmodics and antihistamines, not only for psychiatric drugs, and weak anticholinergics showed no dose pattern.[70] It is still observational, and early, undiagnosed dementia may prompt some of these prescriptions. Even so, it is sensible to minimise long-term use of strong anticholinergics, such as older bladder drugs like oxybutynin and first-generation antihistamines like diphenhydramine, where an alternative exists (Weak for a causal effect; cheap to act on).
A practical brain-health checklist
- Get your hearing screened from age 50: about every 5 years until 64, then every 1–3 years from 65, and sooner if you or others notice a problem. If you fail a screen, get a full hearing assessment.[71]
- Treat hypertension in midlife — target below 130 mmHg systolic if tolerated.
- Treat type 2 diabetes, prediabetes and metabolic syndrome. Without diabetes, an HbA1c (the three-month blood-sugar average) below 5.7% is the normal range. With diabetes, agree an individual target with your clinician. For many adults that is below 7%. People who are frail, have cognitive or functional limitations, or have several serious illnesses are usually given looser goals, such as below 8%, because episodes of low blood sugar are themselves linked to a higher risk of dementia. Pushing HbA1c to near-normal levels with drugs that can cause low blood sugar, such as insulin or sulfonylureas, calls for caution: in the ACCORD trial, intensive lowering raised mortality.[72][73][74]
- Reduce LDL cholesterol through diet, exercise, and statins if indicated.
- Don't smoke. Drink minimally.
- 150+ minutes of aerobic exercise plus two resistance sessions per week, and work toward about 7,000 daily steps — a target, not a floor, since every step below it still counts.
- 7–8 hours of sleep, regular schedule, screen for sleep apnea.
- Mediterranean / MIND-pattern eating — for its cardiovascular benefits; a dementia-specific benefit is unproven (see above). Leafy greens daily, berries twice a week or more, fish, nuts, olive oil, whole grains, beans, poultry. Limit red and processed meat, butter, fried foods, sweets, and ultra-processed food.
- Stay socially connected. Real-world relationships matter.
- Keep learning. Real skills, ideally social and physical — dancing, music, sports, languages.
- Wear seatbelts and helmets; avoid repeated head impacts.
- Reduce air-pollution exposure where feasible: a true-HEPA air cleaner in the bedroom every night, most worthwhile in homes near major roads. See Environmental toxins for the full air-filtration story.
- Get vision corrected. Glasses, cataract surgery, regular eye exams. Vision loss is linked to higher dementia risk, but whether correcting it prevents dementia is unproven: pooled studies of cataract surgery disagree, with one meta-analysis finding no significant reduction in all-cause dementia[75] and another finding about 25% less long-term cognitive decline (hazard ratio 0.75) but at very low to low certainty, with no randomised trial.[76] Correct it for its own sake; any brain benefit is a bonus (Weak). See Vision.
- Treat depression. It carries the highest individual risk of the 14 factors. Therapy, medication, exercise.
Family history of Alzheimer's: what to do
- Most familial risk runs through APOE ε4 carrier status. Genetic testing is available but not always recommended, because the actionable advice is the same whether you're a carrier or not.
- The modifiable factors appear to work equally well in carriers: US POINTER found the cognitive benefit of its structured programme was statistically indistinguishable between APOE ε4 carriers and non-carriers, which is at least consistent with the usual assumption that carriers — starting from higher baseline risk — stand to gain more in absolute terms.
- For specific genetic testing decisions, work with a genetic counsellor.
Further reading
- Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024.[77]
- Lin FR et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE). Lancet 2023.[78]
- Cribb L et al. Treating hearing loss with hearing aids for the prevention of cognitive decline and dementia. Neurology 2026.[79]
- He J et al. Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial. Nat Med 2025.[80]
- SPRINT MIND Investigators. Effect of intensive vs standard blood pressure control on probable dementia. JAMA 2019.[81]
- Ngandu T et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring to prevent cognitive decline in at-risk elderly people (FINGER). Lancet 2015.[82]
- Baker LD et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA 2025.[83]
- Morris MC et al. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's & Dementia 2015.[84]
- Barnes LL et al. Trial of the MIND diet for prevention of cognitive decline in older persons. NEJM 2023.[85]
- Eyting M et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature 2025.[86]
- van Dyck CH et al. Lecanemab in early Alzheimer's disease. NEJM 2023.[87]
- Rebok GW et al. Ten-year effects of the ACTIVE cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc 2014.[88]
- Sutin AR et al. Purpose in life and cognitive health: a 28-year prospective study. Int Psychogeriatr 2024.[89]
- Erickson KI et al. Exercise training increases size of hippocampus and improves memory. PNAS 2011.[90]
- Gogniat MA et al. Sedentary behavior, cognition, and brain health in older adults: a systematic review. Front Aging Neurosci 2025.[91]
- Gogniat MA et al. Increased sedentary behavior is associated with neurodegeneration and worse cognition in older adults over a 7-year period despite high levels of physical activity. Alzheimers Dement 2025.[92]
- Raichlen DA et al. Associations between accelerometer-derived sedentary behavior and physical activity with white matter hyperintensities in middle-aged to older adults. Alzheimers Dement (Amst) 2024.[93]
- Matthews VB et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 2009.[94]
- Rasmussen P et al. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 2009.[95]